

73. Kathleen Staub, Dresher, Pennsylvania, Court of Federal Claims No: 23–1611V
74. Shireesha Eedunuru on behalf of R. R. K., Sugarland, Texas, Court of Federal Claims No: 23–1613V
75. Anna Hoffman, Summit, Wisconsin, Court of Federal Claims No: 23–1614V
76. Sarah Leah Ganzweig, New York, New York, Court of Federal Claims No: 23–1615V
77. Adi Eminente, Los Angeles, California, Court of Federal Claims No: 23–1616V
78. Nancy Hodges, Fresno, California, Court of Federal Claims No: 23–1617V
79. Debora Strader, Escondido, California, Court of Federal Claims No: 23–1619V
80. Dairinn Finn, Olean, New York, Court of Federal Claims No: 23–1620V
81. Gabrielle Rawnsley, Charleston, New Hampshire, Court of Federal Claims No: 23–1621V
82. James A. Bristol, Jr., McKinney, Texas, Court of Federal Claims No: 23–1622V
83. Jamie Whitehouse, Helena, Montana, Court of Federal Claims No: 23–1623V
84. Christal Hanson, Boston, Massachusetts, Court of Federal Claims No: 23–1624V
85. Karen Bergin, New London, Connecticut, Court of Federal Claims No: 23–1625V
86. Amanda Page, Louisburg, North Carolina, Court of Federal Claims No: 23–1626V
87. Nazeer Lotfi-Fard, Avon, Ohio, Court of Federal Claims No: 23–1627V
88. Travis Rian, Wellesley, Massachusetts, Court of Federal Claims No: 23–1628V
89. Eugene Hieger, Lexington, Kentucky, Court of Federal Claims No: 23–1630V
90. Wendy Wright, Lewiston, Idaho, Court of Federal Claims No: 23–1631V
91. Bruce A. Scott, Fort Recovery, Ohio, Court of Federal Claims No: 23–1632V
92. Kathleen Hicks, Mechanicsville, Virginia, Court of Federal Claims No: 23–1634V
93. Rebecca Fellows, Lebanon, New Hampshire, Court of Federal Claims No: 23–1636V
94. Natalie Gaines, Columbia, Maryland, Court of Federal Claims No: 23–1637V
95. Michael Todaro, Dresher, Pennsylvania, Court of Federal Claims No: 23–1638V
96. Nicole Schaefer, Charleston, South Carolina, Court of Federal Claims No: 23–1641V
97. Annie Murphy, Ann Arbor, Michigan, Court of Federal Claims No: 23–1642V
98. Kristena Rivera on behalf of L. R., Dresher, Pennsylvania, Court of Federal Claims No: 23–1644V
99. Kerri Stone on behalf of E. L., Lexington, South Carolina, Court of Federal Claims No: 23–1645V
100. Toni Rankin, Beverly Hills, California, Court of Federal Claims No: 23–1646V
101. Gregory Whitehouse, Boston, Massachusetts, Court of Federal Claims No: 23–1647V
102. Melvin J. Martin on behalf of Billy J. Martin, Deceased, Greensboro, North Carolina, Court of Federal Claims No: 23–1649V
103. James Brady, Boston, Massachusetts, Court of Federal Claims No: 23–1650V
104. Julio Castillo, South Jordan, Utah, Court of Federal Claims No: 23–1651V
105. Jesus Villahermosa, Gig Harbor, Washington, Court of Federal Claims No: 23–1652V
106. Theresa V. Barrows, Cambridge, Vermont, Court of Federal Claims No: 23–1653V
107. Grisel Escalera, Providence, Rhode Island, Court of Federal Claims No: 23–1654V
108. Margaret Carter, Dresher, Pennsylvania, Court of Federal Claims No: 23–1656V
109. Stacy Brown-Satterwhite, Greensboro, North Carolina, Court of Federal Claims No: 23–1658V
110. Jerilynn Vokurka, Phoenix, Arizona, Court of Federal Claims No: 23–1659V
111. Debra Legleiter, Harrison, Arkansas, Court of Federal Claims No: 23–1660V
112. Brenda Smull, Chandler, Arizona, Court of Federal Claims No: 23–1662V
113. Lois Blankenship on behalf of Carter Blankenship, Deceased, Crown Point, Indiana, Court of Federal Claims No: 23–1663V
114. Curtis Lovejoy, Altamont, Illinois, Court of Federal Claims No: 23–1664V
115. Evelyn Fisher, Bensalem, Pennsylvania, Court of Federal Claims No: 23–1665V
116. Mary Palmisano, New Brunswick, New Jersey, Court of Federal Claims No: 23–1666V
117. Alina Dennis, Chula Vista, California, Court of Federal Claims No: 23–1670V
118. Julie Brown, Libertyville, Illinois, Court of Federal Claims No: 23–1671V
119. Raymond Motyka, East Orange, New Jersey, Court of Federal Claims No: 23–1672V
120. Carl Bildner, Columbia, Missouri, Court of Federal Claims No: 23–1673V
121. Deborah Bagdazian, San Diego, California, Court of Federal Claims No: 23–1674V
122. Misty Fuller, Glenwood Springs, Colorado, Court of Federal Claims No: 23–1677V
123. Jeanne Carpenter, Glen Burnie, Maryland, Court of Federal Claims No: 23–1678V
124. John J. Reding, Jr., Seattle, Washington, Court of Federal Claims No: 23–1679V
125. Gina Goldmann, Islandia, New York, Court of Federal Claims No: 23–1681V
126. Bruce W. Blais, Jr., Providence, Rhode Island, Court of Federal Claims No: 23–1682V
127. Von-Ikenna Marie Tresna-Taylor, Fulton, Missouri, Court of Federal Claims No: 23–1687V
128. Kenneth Berard, Vancouver, Washington, Court of Federal Claims No: 23–1690V
129. Bradley McKinnon, Little Rock, Arkansas, Court of Federal Claims No: 23–1691V
130. Melinda Boards, Bowling Green, Kentucky, Court of Federal Claims No: 23–1692V
131. Dora D. Loiacono, West Caldwell, New Jersey, Court of Federal Claims No: 23–1693V

[FR Doc. 2023–25043 Filed 11–13–23; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; Preclinical Proof of Concept Studies for Rare Diseases (R21) Review Meeting.

*Date:* January 24–25, 2024.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Carol (Chang-Sook) Kim, Ph.D., Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, MSC 4874 Bethesda, MD 20892, (301) 402–1744, [carol.kim@nih.gov](mailto:carol.kim@nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: November 8, 2023.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023–25070 Filed 11–13–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR-22-233: Time-Sensitive Opportunities for Health Research.

*Date:* December 8, 2023.

*Time:* 11:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Wenjuan Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 480-8667, wangw22@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 8, 2023.

**Patricia B. Hansberger,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-25072 Filed 11-13-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Proposed Collection; 60-Day Comment Request; Cancer Therapy Evaluation Program (CTEP) Branch and Support Contracts Forms and Surveys (NCI)

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

**FOR FURTHER INFORMATION CONTACT:** To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Michael Montello, Cancer Therapy Evaluation Program—DCTD, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland 20850 or call non-toll-free number (240) 276-6080 or email your request, including your address to: [montellom@mail.nih.gov](mailto:montellom@mail.nih.gov). Formal requests for additional plans and instruments must be requested in writing.

#### SUPPLEMENTARY INFORMATION:

Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*Proposed Collection Title:* Cancer Therapy Evaluation Program (CTEP)

Branch and Support Contracts Forms and Surveys (NCI), 0925-0753, Expiration Date 03/31/2026, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH).

#### *Need and Use of Information*

*Collection:* This is a request for OMB to approve the revised information collection, Cancer Therapy Evaluation Program (CTEP) Support Contracts Forms and Survey. It includes modifications to OMB-approved forms for the CTSU and CIRB and the addition of new forms for the CTSU, CIRB, and CTEP. The National Cancer Institute (NCI) CTEP and the Division of Cancer Prevention (DCP) fund an extensive national program of cancer research, sponsoring clinical trials in cancer prevention, symptom management, and treatment for qualified clinical investigators. As part of this effort, CTEP implements programs to register clinical site investigators and clinical site staff and to oversee the conduct of research at the clinical sites. CTEP and DCP also oversee two support programs, the NCI Central Institutional Review Board (CIRB) and the Cancer Trial Support Unit (CTSU). The combined systems and processes for initiating and managing clinical trials are termed the Clinical Oncology Research Enterprise (CORE) and represent an integrated set of information systems and processes that support investigator registration, trial oversight, patient enrollment, and clinical data collection. The information collected is required to ensure compliance with applicable federal regulations governing the conduct of human subjects' research (45 CFR 46 and 21 CFR 50), and when CTEP acts as the Investigational New Drug (IND) holder (Food and Drug Administration (FDA) regulations pertaining to the sponsor of clinical trials and the selection of qualified investigators under 21 CFR 312.53). Survey collections assess satisfaction and provide feedback to guide improvements with processes and technology.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 162,831 hours.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
CTSU IRB/Regulatory Approval Transmittal Form (Attachment A01).	Health Care Practitioner	2444	12	2/60	978
CTSU IRB Certification Form (Attachment A02) ..	Health Care Practitioner	2444	12	10/60	4888